
Opinion|Videos|October 31, 2024
Prevention and Early Detection of Parkinson’s Disease
Author(s)Stuart H. Isaacson, MD, FAAN
Advertisement
Episodes in this series

Advertisement
Related to this article

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease biomarkers!

A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in glioblastoma beyond extent of resection and sex.

The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.

A published protocol outlines the randomized, open-label EPOCH trial testing whether cilostazol accelerates hematoma resorption and improves recovery after intracerebral hemorrhage.

Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
4
NeurologyLive® Brain Games: September 20, 2026
5



